The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and COPD.

A new study has found that using biologic therapy to reduce lung inflammation enabled 92% of people with severe asthma to reduce their dose of daily inhaled steroid without exacerbating their ...

Eosinophilic exacerbations make up 30% of COPD flare-ups and nearly 50% of asthma attacks, researchers said. During these episodes, amounts of the white blood cells surge in the lungs, causing ...

A phase 4 study found severe asthma can be controlled using biologic therapies, without the addition of high-dose inhaled steroids.

It is currently used for the treatment of severe asthma. The ABRA trial has found a single dose can be more effective when injected at the point of exacerbation compared to steroid tablets.

Stepping down to as-needed ICS/FABA maintained asthma stability while significantly reducing steroid exposure in individuals ...

First New Treatment for Asthma and COPD Flare-Ups in 50 Years Benralizumab reduces steroid use by 30% during eosinophilic asthma and COPD exacerbations, offering a safer treatment.

Asthma diagram, lungs The primary outcome was to compare dupilumab, benralizumab, and mepolizumab in patients with at least 2 pre-index exacerbations. Asthma exacerbations and systemic ...

A landmark study has shown that severe asthma can be controlled using biologic therapies, without the addition of regular high-dose inhaled steroids which can have significant side effects.

The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and COPD.

We’ve used the drug in a different way -- at the point of an exacerbation -- to show that it’s more effective than steroid tablets, which is the only treatment currently available.” ...